CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 51,533 enrolled
Drug / intervention
Montelukast +1 moredrug
Likely dose
Not stated in record
Key inclusion· 4
  • ✓Age ≥65 years at index date
  • ✓No prior use of montelukast and fluticasone before cohort entry
  • ✓Continuous enrollment in Medicare Part A, B, and D without HMO coverage for 365 days before and including cohort entry date
  • ✓At least two asthma diagnosis claims in the 365 days prior to drug initiation
Key exclusion· 2
  • ✕Prior history of dementia at any time before cohort entry
  • ✕Nursing home admission in the 365 days prior to cohort entry date

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05457855
NCT05457855N/ACompleted
CompareCT.gov

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Montelukast vs Fluticasone

Brigham and Women's Hospital·observational·Posted Jul 14, 2022·Updated Aug 11, 2025

In Brief

An observational study evaluating Montelukast and Fluticasone for Asthma. Completed, enrolled 51,533 participants across 1 site.

Detailed Summary

This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA), Rutgers University, Johns Hopkins University

Timeline

N/ACompletedFinished
20222023202420252026
First PostedJul 14, 2022
Enrollment StartFeb 1, 2022
Primary CompletionJul 7, 2023
Study CompletionDec 31, 2023
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 4.0 years ago

Interventions

Montelukastdrug

Montelukast claim is used as the exposure group.

Fluticasonedrug

Fluticasone claim is used as the reference group.